Highlights ReShape Lifesciences OTC Markets

Equities

RSLS

US7611236032

End-of-day quote OTC Markets Other stock markets 18:00:00 2021-07-07 EDT			5-day change	1st Jan Change
5.09 ^USD	+23.84%		-.--%	-.--%

05-15	ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-15	Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M	05-15	MT
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System	03-28	MT
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System	03-28	CI
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex	02-22	CI
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX	12-12	CI
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q3 Revenue $2.2M, vs. Street Est of $2.4M	11-08	MT
ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System	23-09-21	CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q2 Revenue $2.3M, vs. Street Est of $2.6M	23-08-07	MT
ReShape Lifesciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Reshape Lifesciences Inc. Signs Preferred Partner Agreement with Hive Medical for Lead Optimization Software	23-06-29	CI
ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting	23-06-28	CI
ReShape Lifesciences Files US FDA Premarket Approval Supplement Application for Lap-Band 2.0; Shares Surge After Hours	23-06-26	MT
ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-BandÂ® 2.0	23-06-26	CI
ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $2.3M, vs. Street Est of $2.51M	23-05-15	MT
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
North American Morning Briefing : Subdued Open -2-	23-04-17	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ReShape Lifesciences OTC Markets

Equities

RSLS

US7611236032

Highlights

Filters